This study investigates various solid tumors. The purpose of this study is to collect blood and tissue samples from participants to evaluate the effectiveness of molecular residual disease testing.
The study focuses on evaluating the clinical performance of assays in detecting circulating tumor DNA as a marker for disease recurrence and treatment response. It assesses the ability to monitor minimal residual disease across multiple cancer types.
- Who can participate: Adults aged 18 or older with specific types of untreated primary solid tumors, such as breast, lung, or ovarian cancer, may participate. Participants must be able to provide blood samples and consent to the use of residual tumor tissue for research.
- Study details: Participants will provide blood samples for research purposes.
- Study timelines: The study will last up to eight years.
How understandable was the trial content above?
Hard to understand
Easy to understand